Novel leptomycins from a streptomyces strain A92‐308902: Inhibitors of the Nucleo‐cytoplasmic translocation of the HIV‐1 regulatory protein Rev
- 3 November 1997
- journal article
- medicinal and-biological-chemistry
- Published by Wiley in Helvetica Chimica Acta
- Vol. 80 (7), 2157-2167
- https://doi.org/10.1002/hlca.19970800715
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Nucleocytoplasmic Transport of the Rev Protein of Human Immunodeficiency Virus Type 1 Is Dependent on the Activation Domain of the ProteinExperimental Cell Research, 1995
- The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm.Genes & Development, 1994
- The inhibition of C5a receptor binding by analogs of L-156,602, a cyclic hexadepsipeptide antibioticBioorganic & Medicinal Chemistry Letters, 1992
- Preferential Suppression of Delayed-type Hypersensitivity by L-156,602, a C5a Receptor AntagonistBioscience, Biotechnology, and Biochemistry, 1992
- New Colorimetric Cytotoxicity Assay for Anticancer-Drug ScreeningJNCI Journal of the National Cancer Institute, 1990
- Synthesis of the lipophilic side chain of the cyclic hexadepsipeptide antibiotic L-156,602The Journal of Organic Chemistry, 1990
- Effects of leptomycin B on the cell cycle of fibroblasts and fission yeast cellsExperimental Cell Research, 1990
- The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNANature, 1989
- Trans -Activator Gene of Human T-Lymphotropic Virus Type III (HTLV-III)Science, 1985
- Detection, Isolation, and Continuous Production of Cytopathic Retroviruses (HTLV-III) from Patients with AIDS and Pre-AIDSScience, 1984